Characteristic | No mottling n = 451 | Mottling n = 296 | p-value |
---|---|---|---|
Age—years | 65 [54–75] | 69 [58–78] | 0.002 |
Male sex | 302 [67] | 201 [67] | 0.81 |
SAPS II | 53 [43–63] | 63 [50–77] | < 0.0001 |
SOFA | 10 [8–12] | 11 [9–13] | < 0.0001 |
Pre-existing condition—no (%) | |||
Ischemic heart disease | 35 [8] | 43 [14] | 0.003 |
Chronic heart failure | 55 [12] | 53 [18] | 0.03 |
COPD | 63 [14] | 39 [13] | 0.83 |
Chronic kidney disease | 49 [11] | 42 [14] | 0.21 |
Cirrhosis | 29 [6] | 23 [8] | 0.56 |
Chronic arterial hypertension | 208 [46] | 166 [57] | 0.008 |
Cancer or autoimmune disease | 167 [37] | 97 [33] | 0.24 |
Source of infection—no (%) | |||
Lung | 252 [56] | 136 [46] | 0.009 |
Abdomen | 60 [13] | 66 [22] | 0.001 |
Urinary tract | 59 [13] | 26 [9] | 0.08 |
Others | 80 [18] | 68 [23] | 0.09 |
Community-acquired infection—no (%) | 296 [66] | 199 [67] | 0.69 |
Hemodynamic and biochemical variable | |||
Mean arterial pressure -mmHg | 74 [65–83] | 71 [61–81] | 0.01 |
Heart rate—beats/min | 100 [81–117] | 107 [88–126] | < 0.0001 |
Arterial pH | 7.34 [7.28–7.39] | 7 .25 [7.15–7.35] | < 0.0001 |
Serum lactate level—mmol/L | 2 [1.3–3.1] | 3.2 [1.8–5.4] | < 0.0001 |
Fluid therapy before inclusion—mL | 2500 [2000–3250] | 3000 [2500–4000] | < 0.0001 |
Vasoactive drug infusions at randomization—no (%) | |||
Norepinephrine | 434 [96] | 274 [93] | 0.04 |
Dobutamine | 21 [5] | 20 [7] | 0.25 |
Epinephrine | 18 [4] | 36 [12] | 0.0004 |
Median vasopressor dose at randomization—µg/kg/min | |||
Norepinephrine | 0.32 [0.2–0.52] | 0.44 [0.22–0.84] | 0.0004 |
Epinephrine | 0.34 [0.16–0.57] | 0.21 [0.14–0.5] | 0.35 |
Mechanical ventilation—no (%) | 317 [70] | 253 [85] | < 0.0001 |
PaO2/FiO2 ratio -mmHg | 178 [122–267] | 158 [90–245] | 0.0098 |
Acute kidney injury—no (%) | 175 [39] | 169 [57] | < 0.0001 |